Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 1
2012 3
2013 4
2014 7
2015 15
2016 16
2017 14
2018 12
2019 12
2020 15
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

90 results
Results by year
Filters applied: . Clear all
Page 1
Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis.
Fiore M, Alfieri A, Di Franco S, Pace MC, Simeon V, Ingoglia G, Cortegiani A. Fiore M, et al. Among authors: simeon v. Antibiotics (Basel). 2020 Jul 7;9(7):388. doi: 10.3390/antibiotics9070388. Antibiotics (Basel). 2020. PMID: 32645986 Free PMC article.
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
Perrone F, De Laurentiis M, De Placido S, Orditura M, Cinieri S, Riccardi F, Ribecco AS, Putzu C, Del Mastro L, Rossi E, Tinessa V, Mosconi AM, Nuzzo F, Di Rella F, Gravina A, Iodice G, Landi G, Pacilio C, Forestieri V, Lauria R, Fabbri A, Ibrahim T, De Maio E, Barni S, Gori S, Simeon V, Arenare L, Daniele G, Piccirillo MC, Normanno N, de Matteis A, Gallo C. Perrone F, et al. Among authors: simeon v. Eur J Cancer. 2019 Sep;118:178-186. doi: 10.1016/j.ejca.2019.05.004. Epub 2019 Jun 1. Eur J Cancer. 2019. PMID: 31164265 Clinical Trial.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer.
Cardone C, Blauensteiner B, Moreno-Viedma V, Martini G, Simeon V, Vitiello PP, Ciardiello D, Belli V, Matrone N, Troiani T, Morgillo F, Zito Marino F, Dentice M, Nappi A, Boccaccino A, Antoniotti C, Cremolini C, Pietrantonio F, Prager GW, Normanno N, Maiello E, Argiles G, Elez E, Signoriello G, Franco R, Falcone A, Tabernero J, Sibilia M, Ciardiello F, Martinelli E. Cardone C, et al. Among authors: simeon v. Eur J Cancer. 2020 Oct;138:1-10. doi: 10.1016/j.ejca.2020.07.010. Epub 2020 Aug 17. Eur J Cancer. 2020. PMID: 32818762
Antimicrobial Lock Therapy in Clinical Practice: A Scoping Review Protocol.
Alfieri A, Di Franco S, Passavanti MB, Pace MC, Stanga A, Simeon V, Chiodini P, Leone S, Niyas VKM, Fiore M. Alfieri A, et al. Among authors: simeon v. Methods Protoc. 2020 Feb 12;3(1):16. doi: 10.3390/mps3010016. Methods Protoc. 2020. PMID: 32059575 Free PMC article.
90 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page